TITLE

Role of Growth Hormone in Chronic Heart Failure: Therapeutic Implications

AUTHOR(S)
Volterrani, M.; Manelli, F.; Cicoira, M.; Lorusso, R.; Giustina, A.
PUB. DATE
October 2000
SOURCE
Drugs;Oct2000, Vol. 60 Issue 4, p711
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Congestive heart failure is a multiple aetiology, high prevalence, poor prognosis cardiovascular disorder. Medical treatment of dilated cardiomyopathy is aimed at alleviating the symptoms of heart failure. Diuretics, ACE inhibitors and very recently, β-blockers have been shown to have favourable effects on symptoms, exercise capacity and mortality. Growth hormone (GH) and insulin-like growth factor (IGF)-1 are involved in several physiological processes such as the control of muscle mass and function, body composition and regulation of nutrient metabolism. The roles of GH and IGF-1 as modulators of myocardial structure and function are well established. Receptors for both GH and IGF-1 are expressed by cardiac myocytes; therefore, GH may act directly on the heart or via the induction of local or systemic IGF-1, whereas IGF-1 may act by endocrine, paracrine or autocrine mechanisms. Patients with acromegaly have an increased propensity to develop ventricular hypertrophy and cardiovascular diseases and, in addition, an impaired cardiac efficiency is observed in patients with GH deficiency. Animal models of pressure and volume overload have demonstrated up-regulation of cardiac IGF-1 production and expression of GH and IGF-1 receptors, implying that the local regulation of these factors is influenced by haemodynamic changes. Moreover, experimental studies suggest that GH and IGF-1 have stimulatory effects on myocardial contractility, possibly mediated by changes in intracellular calcium handling. Heart failure is caused by ventricular dilatation with abnormal wall thickening, which leads to impaired cardiac performance; therefore, based on the evidence available for GH we would expect beneficial effects from the use of GH in these patients. Several papers highlight the positive influence of GH in the regulation of heart development and performance. In patients with GH deficiency, GH administration dramatically improves cardiac function. In small nonblind studies, both short and long term GH treatment have demonstrated beneficial effects in patients with heart failure secondary to ischaemic or idiophatic cardiomyopathy. Recently, two randomised, placebo-controlled studies, did not show significant GH-mediated improvement in cardiac performance in patients with dilated cardiomyopathy, despite significant increases in IGF-1. Acquired GH resistance, might be an important feature of severe heart failure and explain the different responses to GH therapy seen in different patients. Whether GH treatment will finally find a place, and with which modalities, in the treatment of heart failure remains to be established.
ACCESSION #
9593318

 

Related Articles

  • Chronische Herzinsuffizienz im Alter. Fischer, D.; Dettmer-Flügge, A.; Thiesemann, R.; Gogol, M. // Zeitschrift für Gerontologie und Geriatrie;Jun2011, Vol. 44 Issue 3, p158 

    The incidence of chronic heart failure rises with increasing age as does the proportion of diastolic dysfunction in comparison to heart failure with reduced systolic ejection fraction. Symptoms are less specific, such as fatigue, which makes a diagnosis more difficult but classification and...

  • Ambulatory CHF Patients in Rehabilitation: Cardiopulmonary Approaches. Marcadet, Dany Michel // Clinical & Investigative Medicine;Jun2001 Supplement, Vol. 24, pS38 

    The article discusses the cardiopulmonary approaches in rehabilitating ambulatory chronic heart failure (HF) patients. In a recent past, rehabilitation programs have been developed mostly for coronary patients. These programs play an important role by allowing a rapid recovery of functional...

  • Angina drug reduces deaths in heart failure. Katwala, Amit // GP: General Practitioner;9/3/2010, p8 

    The article presents information on the findings of two studies on cardiology. The studies states that reducing heart rate with ivabradine can reduce the risk of cardiovascular death in heart failure patients. The first study investigated that effects of ivabradine in 6,505 patients with chronic...

  • Optimal glycemic control improves outcomes of chronic heart failure. Wang, Lexin; Owen, Norelle // Internet Journal of Cardiovascular Research;2007, Vol. 4 Issue 2, p1 

    There is a high prevalence of heart failure in patients with diabetes mellitus due to hyperglycemia-induced metabolic disturbances and remodeling of myocardium, as well as increased incidence of ischemic cardiomyopathy. Patients with heart failure and concurrent diabetes have an increased...

  • Beneficial Electrophysiological Effects of Trimetazidine in Patients With Postischemic Chronic Heart Failure. Cera, Michela; Salerno, Anna; Fragasso, Gabriele; Montanaro, Claudia; Gardini, Chiara; Marinosci, Giovanni; Arioli, Francesco; Spoladore, Roberto; Facchini, Alberto; Godino, Cosmo; Margonato, Alberto // Journal of Cardiovascular Pharmacology & Therapeutics;Mar2010, Vol. 15 Issue 1, p24 

    The article discusses a study on the effects of trimetazidine (TMZ) on the dispersion of atrial depolarization and ventricular repolarization. QT interval has been measured on 30 patients with chronic heart failure (CHF), 17 patients received conventional therapy and TMZ while 13 patients took...

  • Pharmacological management of heart failure. Cox, Beverley // Practice Nurse;4/6/2007, Vol. 33 Issue 7, p49 

    This article offers guide on the pharmacological management of heart failure. The main classes of drugs used to improve outcomes in heart failure include: ACE-inhibitors, beta-blockers and aldosterone blockers. All three classes of drug have been proven to improve symptoms, increase longevity...

  • Is the Digital Divide an Obstacle to e-Health? An Analysis of the Situation in Europe and in Italy. Romano, Maria Francesca; Sardella, Maria Vittoria; Alboni, Fabrizio; Russo, Luana; Mariotti, Rita; Nicastro, Irene; Barletta, Valentina; Di Bello, Vitantonio // Telemedicine & e-Health;Jan2015, Vol. 21 Issue 1, p24 

    Introduction: The digital divide affecting elderly patients may compromise the diffusion of telemedicine systems for this age segment. It might be that the difficulties in the passage from trials to the effective distribution of telemedicine systems are also due to the awareness of a personal...

  • A case and review of acromegaly-induced cardiomyopathy and the relationship between growth hormone and heart failure: cause or cure or neither or both? Schwarz, Ernst R.; Jammula, Praveen; Gupta, Rajiv; Rosanio, Salvatore // Journal of Cardiovascular Pharmacology & Therapeutics;Dec2006, Vol. 11 Issue 4, p232 

    Growth hormone plays an integral role in the development and maintenance of structure and function of the heart. Specific involvement of the heart in acromegaly is termed acromegalic cardiomyopathy, manifested as concentric left ventricular hypertrophy and diastolic dys-function. Left untreated,...

  • Ascertainment of chronic diseases using population health data: a comparison of health administrative data and patient self-report. Muggah, Elizabeth; Graves, Erin; Bennett, Carol; Manuel, Douglas G. // BMC Public Health;2013, Vol. 13 Issue 1, p1 

    Background: Health administrative data is increasingly being used for chronic disease surveillance. This study explored agreement between administrative and survey data for ascertainment of seven key chronic diseases, using individually linked data from a large population of individuals in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics